

Structure-based drug discovery with deep learning

Rıza Özçelik^{1,2+}, Derek van Tilborg^{1,2+}, José Jiménez-Luna³, and Francesca Grisoni^{1,2*}

¹Eindhoven University of Technology, Institute for Complex Molecular Systems and Dept. Biomedical Engineering, Eindhoven, Netherlands.

²Centre for Living Technologies, Alliance TU/e, WUR, UU, UMC Utrecht, Netherlands.

³Microsoft Research Cambridge, Cambridge, United Kingdom.

+These authors contributed equally.

*e-mail: f.grisoni@tue.nl

ABSTRACT

Artificial intelligence (AI) in the form of deep learning bears promise for drug discovery and chemical biology, *e.g.*, to predict protein structure and molecular bioactivity, plan organic synthesis, and design molecules *de novo*. While most of the deep learning efforts in drug discovery have focused on ligand-based approaches, structure-based drug discovery has the potential to tackle unsolved challenges, such as affinity prediction for unexplored protein targets, binding-mechanism elucidation, and the rationalization of related chemical kinetic properties. Advances in deep learning methodologies and the availability of accurate predictions for protein tertiary structure advocate for a *renaissance* in structure-based approaches for drug discovery guided by AI. This review summarizes the most prominent algorithmic concepts in structure-based deep learning for drug discovery, and forecasts opportunities, applications, and challenges ahead.

Keywords

Artificial intelligence • De novo design • Machine learning • Medicinal chemistry • Structural biology

Introduction

Deep learning – a subfield of artificial intelligence (AI) based on multi-layer neural networks^[1] – has gained remarkable traction in science and technology, *e.g.*, to advance mathematics^[2,3], investigate galaxies^[4], and generate realistic images^[5]. Chemistry and biology have witnessed several AI breakthroughs, for instance, in protein structure prediction^[6,7], chemical synthesis planning^[8,9], and atomistic simulations^[10,11]. Drug discovery has particularly benefited from the advent of deep learning^[12,13], with success in molecule prioritization and automated *de novo* design^[14–17]. Here, deep learning can accelerate the navigation of the extremely vast chemical space of drug-like molecules^[18] in search for potential therapeutics, and complement resource- and time-intensive high-throughput screening campaigns^[19]. Most deep learning studies have focused on ligand-based approaches^[21], which leverage solely the structural information of small molecule ligands to provide predictions. For these applications, numerous systematic studies^[20,21] and experimental proofs-of-concept^[16,17,22] have been published. On the other hand, structure-based deep learning approaches – which leverage information on the target protein – have not found parallel interest yet.

Structure-based drug discovery (SBDD) methods augmented with AI are arguably a more complex and a higher-potential endeavor compared to their ligand-based counterparts. Numerous marketed drugs have been identified by ‘traditional’ SBDD (*e.g.*, HIV-1 protease inhibitors^[23], the thymidylate synthase inhibitor raltitrexed^[24], and the antibiotic norfloxacin^[25]). Accelerating SBDD with deep learning can help address existing drug discovery challenges, such as polypharmacology by design^[26], selectivity optimization^[27], activity cliff prediction^[28], and target deorphanization^[29]. Deep learning does not require explicit feature engineering and can thus be applied to learn directly from molecular representations of both ligands and proteins. This is particularly relevant for SBDD, where engineering numerical features for complex molecular entities like proteins^[30] is inevitably more laborious than for small molecules^[31]. Therefore, deep learning for SBDD bears an untapped potential to capture highly non-linear structure-activity relationships and has recently started to show its promise. Accurate protein structure prediction efforts like AlphaFold^[6,7] are expected to further accelerate computer-assisted SBDD. Deep learning for SBDD is still in its infancy but is moving forward at a fast pace, and its relevance in the years to come is expected to increase.

This review provides a comprehensive overview of how deep learning can be leveraged for SBDD, to incorporate protein information at different levels of complexity (*e.g.*, aminoacid sequence, and/or tertiary structure). After addressing how proteins can be represented for deep learning, we address current state-of-the-art methods for structure-based drug discovery, with a




Figure 1. Structure-based drug discovery tasks discussed in this review: (a) *drug-target interaction prediction*, which aims to predict the affinity between a protein and a ligand, using the structural information of both molecular entities; (b) *binding site detection*, which aims to identify ‘druggable’ cavities in the protein structure, (c) *de novo design*, aiming to design bioactive molecules from scratch using the information of a protein target.

particular focus on drug-target interaction prediction, binding site detection, and *de novo* design (Fig. 1). Finally, we discuss current limitations and research gaps, along with foreseen future directions and opportunities. A glossary of selected terms can be found in Box 1.

Representing proteins for deep learning

The design of deep learning approaches for SBDD is inherently more intricate than those that are ligand-based, due to the need to represent protein information at different levels of complexity. Proteins are large polypeptide chains, organized in a ‘structural hierarchy’^[36]: (a) *primary structure*, referring to the sequential arrangement of amino acids along the polypeptide chain, (b) *secondary structure*, capturing the occurrence of alpha-helices and beta-pleated sheets along the protein sequence, and (c) *tertiary structure*, capturing how proteins fold in the three-dimensional space. Such complexity is reflected in the various protein representations used for deep learning (Fig. 2):

- *Primary (amino acid) sequence*. The amino acid sequence is specified starting from the amino-terminal end (N-terminus) and ending at the carboxyl-terminal (C-terminus) end. For deep learning purposes, the primary sequence is often represented as a character string, where each letter represents one of the twenty naturally-occurring amino acids (*e.g.*, ‘AIR’ corresponds to alanine, isoleucine, and arginine). These representations are at the core of established protein ‘featurization’ techniques, such as ProtVec^[37], SeqVec^[38], and ProtTrans^[39]. Although less frequently encountered^[40,41], the primary sequence can also be represented as a graph, whose nodes are amino acids (featurized by type or corresponding physicochemical features) and whose edges capture their adjacency in the chain.
- *Tertiary (three-dimensional) structure*. The three-dimensional shape of a protein (tertiary structure) is determined by the interactions among its side chains, and features a certain degree of conformational plasticity^[42]. The protein structure contains key information for SBDD, since it relates to protein function^[43,44], and it determines ligand binding^[45].

Box 1: Glossary of selected terms

Binding site. Protein region that is responsible for the interaction with another molecule (*e.g.*, small molecule inhibitors, activators, and other proteins).

Convolutional neural network (CNN). Neural network architecture that learns from local information on grid-like data through convolution operations.

Molecular docking. Computational procedure used to predict the predominant three-dimensional binding mode(s) of a molecule w.r.t. another (macro)molecule it binds to. These typically involve the use of a conformational search method and pose scoring functions^[32].

Generative deep learning. Deep learning methods that aim to model the underlying data distribution of a given set of samples and, by sampling from the modeled distribution, generate new data points without the need for explicit hard-coded design rules^[33].

Geometric deep learning. Umbrella term to identify neural network architectures that incorporate and process symmetry information in their design^[34].

Molecular descriptors. Numerical features obtained from a molecular representation with the goal of capturing pre-defined chemical information^[31].

Ligand. Any molecule that binds to a protein with high affinity and specificity.

Protein. (Macro)molecule consisting of amino acid residues joined by peptide bonds.

Reinforcement learning. Subfield of machine learning whose goal is to study the agents that learn to act towards maximizing a cumulative reward in an environment.

Simplified Molecular Input Line Entry System (SMILES)^[35]. String-based chemical notation capturing two-dimensional molecular information, in which letters are used to represent atoms, whereas symbols and numbers encode bond types, connectivity, branching, and stereochemistry.

Transfer learning. A machine learning method where a model trained on one task is reused as the starting point for a model on a second, related, task.

Voxel. A volumetric pixel.

Moreover, inducing conformational changes is often the goal of drug discovery^[42]. Several ways exist to learn from tertiary structures with deep learning. Early approaches^[46,47] have used grid-based voxel representations (*see* Box 1) to capture the spatial distribution of the protein's physicochemical or pharmacophore properties. While these representations are suited to well-established deep learning architectures (*e.g.*, convolutional neural networks, CNNs), many voxels representing empty space do not carry relevant information, and they involve increased computational costs at higher spatial grid resolutions. Other approaches^[48] represent proteins as molecular graphs, where each atom is a node and each bond is an edge. Depending on the chosen level of coarse-graining, often only backbone atoms are chosen to correspond to nodes, while edges often represent geometrical proximity in the coordinate space rather than direct chemical bonds^[49]. Edges and bonds can be characterized by additional geometrical and/or physicochemical properties.

- **Protein surface.** The protein surface is usually defined as the separation between solvent-accessible and inaccessible regions^[50,51] (Fig. 2a) and it plays a key role in the protein interactions with (macro)molecular entities. Protein surfaces are usually represented as either meshes (*i.e.*, a set of polygons capturing the location of the surface, whose vertices can be described by a 2D grid or a 3D graph structure) or point clouds (*i.e.*, graphs whose nodes describe the location of the surface at a certain resolution). Although often computed from the 3D structure, the surface representation might better reflect the physicochemical features responsible for the interaction with other (macro)molecules, as well as aspects of protein function that go beyond sequence similarity.

The chosen protein representation for deep learning affects the *type*, *quality*, and *quantity* of chemical information captured. It will also affect the type of suitable deep learning strategies (Box 2) and the corresponding advantages and drawbacks. Additionally, the number of data available for machine learning depends on the chosen protein representation (Table 1). Primary sequences are easy to obtain but lack information about the spatial configuration of atoms, particularly relevant to determine the binding pose of ligands. On the other hand, 3D protein structures contain potentially richer information for drug discovery, but they are more difficult to obtain experimentally and thus relatively scarce (although the cost has been steadily decreasing with the advent of experimental techniques like cryogenic electron microscopy^[52]). In this context, AI breakthroughs in protein structure prediction like AlphaFold^[6] bear promise to bridge the gap in data availability, by making thousands of predicted protein structures available in an unprecedented effort^[53,54].

Small molecule ligands can be represented in analogous ways to protein structures. The most commonly used representations are: (a) molecular strings (*e.g.*, SMILES strings^[35]), which capture 2D information (atom occurrence and connectivity), (b) 2D and 3D molecular graphs (based on the availability of experimentally determined or computed conformational information), and (c) molecular surfaces. An in-depth description of small molecule representations and corresponding deep learning approaches




Figure 2. Representing proteins for deep learning. (a) Structural hierarchy of protein information: (*primary*) amino-acid sequence, referring to the sequential arrangement of amino acids along the polypeptide chain; (*tertiary*) 3D structure, capturing protein folding in the three-dimensional space; *protein surface*, delimiting solvent-accessible and inaccessible regions. Each level of information is characterized by a different availability of data (1). (b) Protein representations for deep learning, capturing information on the protein sequence (*strings*), the 3D structure (*graphs*, *voxels* and *point clouds*), and the surface (*point clouds* and *meshes*). Each representation is suited to different neural network architectures (Box 2).

can be found in a recent work^[55].

Deep learning for structure-based drug discovery

This section aims to provide a concise overview of SBDD approaches fueled by deep learning. SBDD will be considered in its broader sense, *i.e.*, not only limited to 3D protein structure, but also including sequence and surface representations. We focus on three key tasks (Fig. 1), namely binding site detection, drug-target interaction prediction, and structure-based *de novo* design. For each task, selected deep learning approaches are described through the lenses of the protein representation they rely on (sequence, structure, or surface). A summary of selected deep learning studies is reported in Table 2.

Drug-target interaction prediction

The identification of interactions between molecules and macromolecular targets is a key step in drug discovery, drug repurposing, and off-target activity prediction. Drug-target interaction (DTI) prediction aims to predict the bioactivity (*e.g.*, binding affinity) of a given set of molecules on one or more macromolecular targets, by leveraging both protein and ligand information. Given the complexity of ligand-protein interactions and of engineering suitable molecular features for DTI, it is no surprise that this topic has found a widespread application of deep learning techniques^[105]. In what follows, deep learning models developed for DTI prediction are categorized on the basis of the protein representation they rely on.

- *Sequence-based approaches.* Sequence-based DTI prediction models use amino acid sequences in combination with ligand representations to perform a prediction. One of the earliest approaches, DeepDTA^[69], applied 1-dimensional CNNs to simultaneously learn from string representations of both ligands (in the form of SMILES) and protein sequence, by first creating separated embeddings and then concatenating them to perform a prediction. Later works have replaced CNNs with other methods, such as recurrent neural networks (Box 2),^[70,106] and attention-based^[70,106,107] or transformer architectures^[71,72,108]. Several works have addressed how to improve the representation of protein sequences, *e.g.*, by incorporating evolutionary information,^[109,110] or protein sequence composition descriptors^[73,111]. Ligands are usually represented as strings (*e.g.*, SMILES^[69,110] or DeepSMILES^[109,112]), binary fingerprints,^[73,113] frequently occurring substructures^[109], or molecular graphs.^[111,114,115]

Table 1. Summary of selected datasets for structure-based deep learning. Dataset name, description and number of entries (updated as of June 2022) are provided.

Dataset	Description	No. entries	Link (if available)
<i>Protein Data Bank (PDB)</i> ^[56]	Structural data of biological macromolecules.	189,735 structures	rcsb.org
<i>scPDB</i> ^[57]	Druggable binding sites and ligands extracted from the PDB.	4782 protein structures and 6326 ligands.	bioinfo-pharma.u-strasbg.fr/scPDB
<i>BioLip</i> ^[58]	Semi-manually curated ligand–protein interactions.	573,225 entries.	zhanggroup.org/BioLiP
<i>PDBbind</i> ^[59]	Protein-ligand co-complexes and associated affinities extracted from the PDB.	23,496 complexes.	pdbbind.org.cn
<i>UniProt</i> ^[59]	Protein sequence and functional information.	> 60 million sequences.	uniprot.org
<i>AlphaFold Protein Structure Database</i> ^[53]	Predictions of protein structures by AlphaFold v 2.0. ^[6]	992,316 predicted structures.	alphafold.ebi.ac.uk
<i>AlphaFill</i> ^[54]	Common ligands and cofactor transplants for AlphaFold models.	12,029,789 transplants.	alphafill.eu
<i>Binding MOAD</i> ^[60,61]	X-ray crystal structures with bound ligands and experimental binding affinities.	41,409 protein-ligand complexes, and 15,223 binding measurements.	bindingmoad.org
<i>Directory of Useful Decoys (DUD-E)</i> ^[62]	Directory of decoys designed to benchmark molecular docking programs.	22,886 active molecules and affinities on 102 targets; 59 decoys per compound.	dude.docking.org
<i>BindingDB</i> ^[63]	Binding affinities of protein-ligand pairs curated from the literature.	~1200 series with at least 1 cocrystal available in each.	bindingdb.org
<i>BigBind</i> ^[64]	Associated protein structures to ChEMBL ^[65] assay data via Pocketome. ^[66]	818,995 activities with associated protein structures.	Brocidiacono <i>et al.</i> , 2022
<i>KIBA</i> ^[67]	Bioactivity measurements of compounds against kinases.	246,088 measurements.	Tang <i>et al.</i> , 2014
<i>Davis</i> ^[68]	Binding affinities (K_d values) of inhibitors against kinases.	30,056 measurements.	Davis <i>et al.</i> , 2011

- *3D structure-based approaches.* These models leverage atom coordinates, usually of co-crystallized protein-ligand complexes, for training. Early approaches projected 3D protein-ligand complexes into grids featurized with physicochemical properties, and subsequently applied CNNs for binding affinity prediction^[46,75,116]. Later works extended this idea by including more sophisticated features, *e.g.*, inter-molecular interaction fingerprints^[76] and computed molecular energies^[117]. 3D grid-based approaches have also been used for lead optimization by predicting relative binding free energies linked to small modifications of ligand structures^[118,119]. More recent approaches have replaced grid-based representations with graphs^[48,77,78,120], allowing to explicitly represent atom neighborhoods and connectivity, and apply roto-translational invariant graph neural networks for binding affinity prediction.
- *Surface-based approaches.* Surface-based approaches have found limited application for DTI prediction. OctSurf^[121] represents both binding pockets and ligands as surfaces, by partitioning the 3D space recursively into octants and considering only portions containing van der Waals surface points. Non-empty octants, along with their physicochemical and geometric features, are then used as the input to a CNN. Other approaches, such as HoloProt^[122], merge 3D structure (graph) and surface (point cloud) information for task-specific training, *e.g.*, enzyme-catalyzed reaction classification and

Table 2. Selected deep learning approaches applied to SBDD. Models are categorized by task and frequently adopted molecular representations.

Task	Description	Protein representation
<i>Drug-target interaction prediction</i>	Predict the interaction between one or more proteins and one or more ligands.	Amino-acid sequence ^[69–74] 3D structure ^[46,75–78]
<i>Docking</i>	Determination of a ligand pose within a target binding site.	3D structure ^[79–81]
<i>Binding site detection</i>	Identification and/or localization of functional protein binding sites.	Amino-acid sequence ^[70,82–84] 3D structure ^[47,85–88] Surface ^[89–91]
<i>De novo design</i>	Generation of ligands with desired properties conditioned on a protein.	Amino-acid sequence ^[92,93] 3D structure ^[94–104]

binding affinity prediction.

Another topic of recent interest by the deep learning community is *protein-ligand docking*, which aims to predict the putative binding pose of a ligand upon binding to a macromolecular target (Box 1). Although these methods do not aim to predict the affinity between a ligand-protein pair directly, they can be used as a proxy to elucidate potential mechanisms of interaction. Deep learning has been mostly applied to ligand pose optimization while considering a rigid target structure, although recent approaches have started taking side-chain flexibility into account^[123]. Early approaches used protein-ligand interaction fingerprints^[124,125], while successive approaches have leveraged either a voxelized version of the protein structure combined with CNNs^[126,127] or graph-based representations with message-passing neural networks^[128–131] in lieu of classical scoring functions. Finally, several approaches have attempted to directly predict the ligand binding pose in an end-to-end fashion^[79,80,132], without the need for a classical search algorithm by exploiting advances in equivariant deep learning.

Deep learning has undoubtedly accelerated DTI prediction, thanks to the possibility to represent and learn from protein-ligand complexes more efficiently. However, simpler models based on well-established descriptors might reach comparable performance^[133], due to undesired memorization and hidden bias in ligand-protein interaction data^[134–137]. Moreover, no relationship has been observed between the complexity of protein and ligand representations and the accuracy of the resulting deep learning models^[133]. Thus, more attention should be put on strategies for model evaluation and data selection/splitting procedures to ensure a reliable prediction of DTIs with deep learning^[133,138,139].

Binding site detection

The identification of ‘druggable’ binding sites in proteins plays a pivotal role in SBDD, from hit identification and molecule screening to mechanism formulation^[140]. Over the years, a plethora of methods have been developed for binding site detection^[140–144], *e.g.*, via interatomic gap volumes^[142] or regions of buried pocket surfaces^[145]. Recently, deep learning methods learning directly from ‘raw’ representations of proteins have gained increasing traction to detect binding sites. These approaches can be grouped by the molecular representations they rely on, *i.e.*, protein sequence, 3D structure, and surface, as described below:

- *Sequence-based models.* Binding site detection can be performed by predicting which residues of the amino-acid sequence are involved in ligand binding, although sequence-based approaches have found limited application. Early methods approached binding site detection as a ‘side-product’ of binding affinity prediction, by using explainable AI techniques to highlight relevant residues for a model’s prediction^[70,82,83]. Few works have addressed binding site detection only^[146,147]. Recently, sequence-based binding site detection has been jointly modeled with drug-target affinity prediction, leading to improved performance on both tasks^[84].
- *3D structure-based models,* which use the spatial information of proteins to detect likely binding sites. Early approaches represented the protein structure with voxels featurized with pharmacophore-like properties, along with convolutional neural networks^[47,85]. Subsequent works have refined structure-based binding site detection with additional techniques from the computer vision domain, *e.g.*, image segmentation.^[86,87] BiteNet^[148] extended ‘static’ CNN-based approaches by incorporating conformational ensembles of proteins. The approach was later adapted to predict protein-peptide binding sites^[149]. A recent approach combined spatial properties with amino acid sequence information to predict protein-protein interaction sites and is applicable to ligand binding site prediction^[88].

- *Surface-based models.* Voxelized representations of protein coordinates have several drawbacks,^[91,150] (e.g., carrying non-informative voxels that are either deeply buried and not accessible by a ligand or represent empty space, and information coarse-graining due to discretization of the input protein space) and might lead to worse results than working with surfaces alone^[150]. For this reason, several methods based on protein surfaces have been developed over the years. These approaches rely on the representation of protein structures as continuous shapes characterized by geometric and physicochemical features to perform a prediction. Geodesic CNNs have been used to determine interaction fingerprints of molecular surfaces, and to predict protein and ligand binding sites^[89]. The approach was later expanded to obtain fully-learnable protein representations.^[90] DeepSurf^[91] discretizes the solvent accessible surface using a combination of K-means clustering and density reduction^[91].

A recent analysis of computational approaches for protein-ligand binding site recognition^[151] has shown DeepSurf^[91] to perform remarkably well. Moreover, non-machine-learning algorithms resulted competitive alternatives to deep learning^[151]. All analyzed methods struggled on shallow binding sites, due to the higher frequency of deep grooves used for model training^[151]. Despite the recent progress of binding pocket detection, room for improvement remains, e.g., to increase pocket coverage and detect sub-pockets^[151], and to predict allosteric binding sites^[152].

Protein-based *de novo* design

De novo design refers to the generation of novel chemical entities possessing desired properties from scratch^[153] and is among the most challenging tasks in computer-assisted drug discovery. Computational algorithms are faced with an incredibly vast ‘chemical universe’, whose cardinality has been estimated between 10^{24} and 10^{100} molecules^[18,154,155]. In this context, ‘brute-force’ molecule assembly or enumeration approaches are computationally unfeasible. In recent years, generative deep learning has shown great promise for *de novo* drug design^[15,17,156] and to complement traditional approaches based on human-engineered rules^[24,157–159].

Generative deep learning approaches for *de novo* design are usually applied to produce molecules in the form of molecular graphs^[160–162] or strings^[15–17] (e.g., SMILES). While most *de novo* design approaches are ligand-based^[15,156,163–166], structure-based approaches have recently emerged as a promising research direction, due to their potential to design molecules interacting with pharmacologically-relevant targets on demand.


- *Sequence-based approaches.* Sequence-based *de novo* design approaches usually cast the problem into a machine translation task, where high-affinity protein-ligand pairs are considered as sentences in different languages to be matched. To this end, sequence and SMILES strings for proteins and ligands are used, respectively. The first-in-kind approach^[92] trained a transformer architecture to ‘translate’ amino-acid sequences into the SMILES strings of the corresponding ligand. This approach can be used for sequence-conditioned *de novo* design. A recent work used a transformer-based pipeline^[93] that combined language models that were pre-trained on large corpora of proteins^[167] and small molecules^[168].
- *3D structure-based approaches.* *De novo* design conditioned on the tertiary structure information can usually generate molecules in the form of 3D ligands (molecular graphs) or strings (e.g., SMILES). In the former case, 3D representations of protein-ligand complexes are used as the input to generate novel 3D molecular graphs. As one of the earliest approaches, LigVoxel^[94] relied on 3D grids to generate spatial ‘blobs’ of ligand properties such as occupancy, aromaticity, and hydrogen-bond donor/acceptors that match the protein pocket. Later works used equivariant diffusion networks^[103,104], variational autoencoders^[95], and reinforcement learning^[96,97] to directly generate ligand conformations for the binding pocket. Recently, equivariant neural networks coupled with point-cloud representations have been used for molecule optimization, via pocket-based fragment expansion^[169]. Compared to 3D graphs, molecular strings are usually easier to generate and might match or outperform graph-based models^[170]. A pioneering work of this category leverages generative adversarial networks^[171] to produce SMILES strings for protein pockets, where a pocket is featurized and fed into a generator network with a conditioning ligand^[99]. A subsequent model adopts graph neural networks to represent active sites and generates targeted SMILES strings^[101], whereas another model uses a pharmacophore model to represent ligands and condition the generation for the targeted pocket^[100]. Recently^[102], a recurrent neural network model has been coupled with ligand–protein interaction fingerprints (determined on ligand docking poses) for conditioned ligand generation in the form of SMILES strings.

While ligand-based *de novo* design pipelines using deep learning have been experimentally validated in multiple instances^[17,172,173], structure-based *de novo* design has to date not been applied prospectively. This highlights an important gap in the potential for acceptance of structure-based *de novo* design algorithms.

Box 2: Simplified depiction of common neural networks applied to protein representations.

Each protein representation useful for SBDD (Fig. 2) is suited to different neural network architectures. Well-established examples of such architectures are the following:

- Recurrent neural networks (RNNs)* (e.g., with long-short term memory cells^[174]) are commonly-chosen architecture to process the primary sequence of a protein. RNNs incorporate feedback connections that allow information in the previous inputs to flow into the subsequent inputs. The feedback mechanism behaves as a ‘learned memory’ in the architecture and enables capturing long-range dependencies in the input sequence.
- Convolutional neural networks (CNNs)* are a powerful architecture when paired with voxelized representations to capture spatial dependencies. CNNs apply learnable filters to the input and excel in capturing local patterns, which renders them suited to binding affinity prediction and binding site detection.
- Graph neural networks (GNNs)* operate on molecular graphs (e.g., atoms and their interactions) and can capture the structural and functional relationships between, as well as within, atoms belonging to one or more molecular complexes. The wide application domain of graphs enables GNNs to find applications in every task of structure-based drug discovery.



Gaps, opportunities, and outlook

Deep learning for structure-based drug discovery is gaining increasing traction, as evidenced by the exponential increase in the number of published approaches over the last few years. Breakthroughs in protein structure prediction^[7,53] not only exemplify the potential of deep learning in the molecular sciences but are expected to further propel structure-based drug discovery with AI. SBDD is arguably more challenging than its ligand-based counterpart, due to the number and structural complexity of chemical entities involved, and aspects like target conformational flexibility^[175]. Most of the current SBDD algorithms are agnostic to dynamical information and, in certain instances, might not outperform simpler methods^[133,151]. However, SBDD has an untapped potential to tackle drug discovery for new, uncharted protein targets. Such a ‘zero-’ and ‘few-shot’ learning potential makes AI-driven SBDD a high-risk/high-gain endeavor, expected to advance future drug discovery.

An area of continuous development that bears promise for SBDD is geometric deep learning^[34,176]. Geometric deep learning attempts to unify neural networks from the perspective of symmetry and topology. Roto-translational invariance/equivariance is particularly relevant for the three-dimensional representations of molecular systems, which is beneficial to limit function search

space during training^[55]. Geometric deep learning is expected to boost AI's capability to model molecular complexes and their interactions^[89,177], as well as molecular design^[104,178]. Diffusion models^[179] – a family of generative models inspired by non-equilibrium thermodynamics – are also gaining increasing popularity in deep learning thanks to their generative capabilities, and have found pioneering applications in the molecular sciences, too^[81,104,180]. These approaches have reached state-of-the-art in several deep learning applications and are expected to propel SBDD in the future.

A current bottleneck of AI-driven SBDD is constituted by the available training data. While protein sequence information and experimental assay data are largely available, high-quality 3D data of co-crystallized proteins and ligands with accompanying properties is largely missing. Furthermore, obtaining high-quality protein structure information is resource-intensive and challenging for several drug targets^[181], *e.g.*, disordered and membrane proteins. Furthermore, non- and poorly binding molecules are often strongly under-reported in medicinal chemistry datasets. As a result, available three-dimensional datasets are often highly biased in their content^[134–137,182], which has historically led to poor generalizability^[183–186]. Several studies have attempted to alleviate this issue, via data curation^[185,187], bias-controlled training^[98], and debiasing^[138,188]. Bridging the gap between the different types of available information will be an active task in upcoming years, with some recent work pointing in this direction already^[64].

Finally, the application of deep learning in well-established fields like chemical biology and medicinal chemistry might at times be met with skepticism by experimentalists. These well-grounded concerns commonly originate from the black-box nature of deep learning. Additionally, robust performance benchmarks and evaluation datasets are currently missing, especially for *de novo* design studies. Moreover, to the best of our knowledge, no deep learning approaches for SBDD have been validated in a prospective setting yet. To foster broader acceptance of structure-based deep learning, we need to 'open the box' and validate methods experimentally. We envision that more sophisticated applications of explainable AI^[189,190] will aid in identifying underlying structure-activity relationships and binding modes, and bridging the gap between theory and real-world applications.

Conclusions

In recent years, deep learning has taken drug discovery by storm, offering new opportunities for more efficient exploration of chemical space. Ligand binding site detection, drug-target interaction prediction, and structure-based *de novo* design can be valuable tools in early drug discovery, especially for unexplored macromolecular targets. As a whole, these approaches bear great promise to extend upon the successes of ligand-based methods. However, structure-based methods have not yet proven their applicability in prospective scenarios. Overcoming such barriers will mostly depend on additional efforts in data collection and curation, as well as on methodologies that efficiently exploit relationships between assay and structural data.

Acknowledgements

F.G. acknowledges the support from the Institute for Complex Molecular Systems (ICMS, TU/e) and the Centre for Living Technologies (Alliance TU/e, WUR, UU, UMC Utrecht).

Conflict of interest

None to declare.

Author contribution

Conceptualization: F.G., with contributions from all authors; *Investigation*: all authors; *Visualization*: D.v.T., R.O., F.G.; *Writing – original draft*: F.G., R.O., D.v.T.; *Writing – review & editing*: all authors.

List of abbreviations

AI: Artificial intelligence.
CNN: Convolutional neural network.
DTI: Drug-target interaction prediction.
GNN: Graph Neural Network.
SBDD: Structure-based drug discovery.
SMILES: Simplified molecular input line entry system.
RNN: Recurrent Neural Network.
2D (3D): Two- (three-)dimensional.

References

1. LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. *Nature* **521**, 436–444 (2015).
2. Davies, A. *et al.* Advancing mathematics by guiding human intuition with ai. *Nature* **600**, 70–74 (2021).
3. Fawzi, A. *et al.* Discovering faster matrix multiplication algorithms with reinforcement learning. *Nature* **610**, 47–53 (2022).
4. Ho, M. *et al.* The dynamical mass of the coma cluster from deep learning. *Nat. Astron.* **6**, 936–941 (2022).
5. Gregor, K., Danihelka, I., Graves, A., Rezende, D. & Wierstra, D. Draw: A recurrent neural network for image generation. In *International conference on machine learning*, 1462–1471 (PMLR, 2015).
6. Jumper, J. *et al.* Highly accurate protein structure prediction with alphafold. *Nature* **596**, 583–589 (2021).
7. Baek, M. *et al.* Accurate prediction of protein structures and interactions using a three-track neural network. *Science* **373**, 871–876 (2021).
8. Segler, M. H., Preuss, M. & Waller, M. P. Planning chemical syntheses with deep neural networks and symbolic AI. *Nature* **555**, 604–610 (2018).
9. Coley, C. W., Barzilay, R., Jaakkola, T. S., Green, W. H. & Jensen, K. F. Prediction of organic reaction outcomes using machine learning. *ACS central science* **3**, 434–443 (2017).
10. Batatia, I., Kovács, D. P., Simm, G. N., Ortner, C. & Csányi, G. Mace: Higher order equivariant message passing neural networks for fast and accurate force fields. *arXiv preprint arXiv:2206.07697* (2022).
11. Batzner, S. *et al.* E (3)-equivariant graph neural networks for data-efficient and accurate interatomic potentials. *Nat. communications* **13**, 1–11 (2022).
12. Jiménez-Luna, J., Grisoni, F., Weskamp, N. & Schneider, G. Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert. Opin. on Drug Discov.* **16**, 949–959 (2021).
13. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M. & Blaschke, T. The rise of deep learning in drug discovery. *Drug Discov. Today* **23**, 1241–1250 (2018).
14. Stokes, J. M. *et al.* A deep learning approach to antibiotic discovery. *Cell* **180**, 688–702.e13 (2020).
15. Segler, M. H. S., Kogej, T., Tyrchan, C. & Waller, M. P. Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Cent. Sci.* **4**, 120–131 (2018).
16. Yuan, W. *et al.* Chemical space mimicry for drug discovery. *J. Chem. Inf. Model.* **57**, 875–882 (2017).
17. Merk, D., Friedrich, L., Grisoni, F. & Schneider, G. De novo design of bioactive small molecules by artificial intelligence. *Mol. Informatics* **37**, 1700153 (2018).
18. Dobson, C. M. *et al.* Chemical space and biology. *Nature* **432**, 824–828 (2004).
19. Schneider, G. Automating drug discovery. *Nat. reviews drug discovery* **17**, 97–113 (2018).
20. Wu, Z. *et al.* Moleculenet: a benchmark for molecular machine learning. *Chem. science* **9**, 513–530 (2018).
21. Brown, N., Fiscato, M., Segler, M. H. & Vaucher, A. C. Guacamol: benchmarking models for de novo molecular design. *J. chemical information modeling* **59**, 1096–1108 (2019).
22. Zhavoronkov, A. *et al.* Deep learning enables rapid identification of potent ddr1 kinase inhibitors. *Nat. biotechnology* **37**, 1038–1040 (2019).
23. Wlodawer, A. & Vondrasek, J. Inhibitors of hiv-1 protease: a major success of structure-assisted drug design. *Annu. review biophysics biomolecular structure* **27**, 249–284 (1998).
24. Anderson, A. C. The process of structure-based drug design. *Chem. & biology* **10**, 787–797 (2003).

25. Rutenber, E. E. & Stroud, R. M. Binding of the anticancer drug zd1694 to e. coli thymidylate synthase: assessing specificity and affinity. *Structure* **4**, 1317–1324 (1996).
26. Reddy, A. S. & Zhang, S. Polypharmacology: drug discovery for the future. *Expert. review clinical pharmacology* **6**, 41–47 (2013).
27. Kawasaki, Y. & Freire, E. Finding a better path to drug selectivity. *Drug Discov. Today* **16**, 985–990 (2011).
28. van Tilborg, D., Alenicheva, A. & Grisoni, F. Exposing the limitations of molecular machine learning with activity cliffs. *J. Chem. Inf. Model.* **62**, 5938–5951 (2022).
29. Civelli, O. *et al.* G protein–coupled receptor deorphanizations. *Annu. review pharmacology toxicology* **53**, 127 (2013).
30. Kurgan, L. & Miri Disfani, F. Structural protein descriptors in 1-dimension and their sequence-based predictions. *Curr. Protein Pept. Sci.* **12**, 470–489 (2011).
31. Todeschini, R. & Consonni, V. *Molecular Descriptors for Chemoinformaticss* (Wiley-VCH, 2009).
32. Morris, G. M. & Lim-Wilby, M. Molecular docking. In *Molecular modeling of proteins*, 365–382 (Springer, 2008).
33. Foster, D. *Generative deep learning: teaching machines to paint, write, compose, and play* (O’Reilly Media, 2019).
34. Bronstein, M. M., Bruna, J., Cohen, T. & Velicković, P. Geometric deep learning: Grids, groups, graphs, geodesics, and gauges. *arXiv preprint arXiv:2104.13478* (2021).
35. Weininger, D. Smiles, a chemical language and information system. 1. introduction to methodology and encoding rules. *J. chemical information computer sciences* **28**, 31–36 (1988).
36. Branden, C. I. & Tooze, J. *Introduction to protein structure* (Garland Science, 2012).
37. Asgari, E. & Mofrad, M. R. Continuous distributed representation of biological sequences for deep proteomics and genomics. *PloS one* **10**, e0141287 (2015).
38. Heinzinger, M. *et al.* Modeling aspects of the language of life through transfer-learning protein sequences. *BMC bioinformatics* **20**, 1–17 (2019).
39. Elnaggar, A. *et al.* Prottrans: towards cracking the language of life’s code through self-supervised deep learning and high performance computing. *arXiv preprint arXiv:2007.06225* (2020).
40. Borgwardt, K. M. *et al.* Protein function prediction via graph kernels. *Bioinformatics* **21**, i47–i56 (2005).
41. Ingraham, J., Garg, V., Barzilay, R. & Jaakkola, T. Generative models for graph-based protein design. *Adv. neural information processing systems* **32** (2019).
42. Teague, S. J. Implications of protein flexibility for drug discovery. *Nat. reviews Drug discovery* **2**, 527–541 (2003).
43. Orengo, C. A. *et al.* The CATH Database provides insights into protein structure/function relationships. *Nucleic Acids Res.* **27**, 275–279, DOI: 10.1093/nar/27.1.275 (1999). <https://academic.oup.com/nar/article-pdf/27/1/275/4065073/27-1-275.pdf>.
44. Orellana, L. Large-scale conformational changes and protein function: breaking the in silico barrier. *Front. molecular biosciences* **6**, 117 (2019).
45. Di Cera, E. Mechanisms of ligand binding. *Biophys. Rev.* **1**, 011303 (2020).
46. Ragoza, M., Hochuli, J., Idrobo, E., Sunseri, J. & Koes, D. R. Protein–ligand scoring with convolutional neural networks. *J. chemical information modeling* **57**, 942–957 (2017).
47. Jiménez, J., Doerr, S., Martínez-Rosell, G., Rose, A. S. & De Fabritiis, G. DeepSite: protein-binding site predictor using 3D-convolutional neural networks. *Bioinformatics* **33**, 3036–3042 (2017).
48. Feinberg, E. N. *et al.* Potentialnet for molecular property prediction. *ACS central science* **4**, 1520–1530 (2018).

49. Kong, X., Huang, W. & Liu, Y. Conditional antibody design as 3d equivariant graph translation. *arXiv preprint arXiv:2208.06073* (2022).
50. Lee, B. & Richards, F. M. The interpretation of protein structures: estimation of static accessibility. *J. molecular biology* **55**, 379–IN4 (1971).
51. Connolly, M. L. Analytical molecular surface calculation. *J. applied crystallography* **16**, 548–558 (1983).
52. Renaud, J.-P. *et al.* Cryo-em in drug discovery: achievements, limitations and prospects. *Nat. reviews Drug discovery* **17**, 471–492 (2018).
53. Varadi, M. *et al.* Alphafold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic acids research* **50**, D439–D444 (2022).
54. Hekkelman, M. L., de Vries, I., Joosten, R. P. & Perrakis, A. Alphafill: enriching the alphafold models with ligands and co-factors. *bioRxiv* (2021).
55. Atz, K., Grisoni, F. & Schneider, G. Geometric deep learning on molecular representations. *Nat. Mach. Intell.* **3**, 1023–1032 (2021).
56. Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide protein data bank. *Nat. Struct. & Mol. Biol.* **10**, 980–980 (2003).
57. Desaphy, J., Bret, G., Rognan, D. & Kellenberger, E. sc-PDB: a 3D-database of ligandable binding sites—10 years on. *Nucleic Acids Res.* **43**, D399–D404 (2014).
58. Yang, J., Roy, A. & Zhang, Y. BioLiP: a semi-manually curated database for biologically relevant ligand–protein interactions. *Nucleic acids research* **41**, D1096–D1103 (2012).
59. Wang, R., Fang, X., Lu, Y. & Wang, S. The pdbbind database: Collection of binding affinities for protein- ligand complexes with known three-dimensional structures. *J. medicinal chemistry* **47**, 2977–2980 (2004).
60. Benson, M. L. *et al.* Binding MOAD, a high-quality protein–ligand database. *Nucleic Acids Res.* **36**, D674–D678 (2007).
61. Smith, R. D. *et al.* Updates to binding moad (mother of all databases): Polypharmacology tools and their utility in drug repurposing. *J. Mol. Biol.* **431**, 2423–2433 (2019). Computation Resources for Molecular Biology.
62. Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful decoys, enhanced (dud-e): better ligands and decoys for better benchmarking. *J. medicinal chemistry* **55**, 6582–6594 (2012).
63. Liu, T., Lin, Y., Wen, X., Jorissen, R. N. & Gilson, M. K. Bindingdb: A web-accessible database of experimentally determined protein–ligand binding affinities. *Nucleic Acids Res.* **35**, D198–D201 (2007).
64. Brocidiacono, M. *et al.* Bigbind: Learning from nonstructural data for structure-based virtual screening. *ChemRxiv* (2022).
65. Gaulton, A. *et al.* ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic acids research* **40**, D1100–D1107 (2012).
66. Kufareva, I., Ilatovskiy, A. V. & Abagyan, R. Pocketome: an encyclopedia of small-molecule binding sites in 4d. *Nucleic acids research* **40**, D535–D540 (2012).
67. Tang, J. *et al.* Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. *J. Chem. Inf. Model.* **54**, 735–743 (2014).
68. Davis, M. I. *et al.* Comprehensive analysis of kinase inhibitor selectivity. *Nat. biotechnology* **29**, 1046–1051 (2011).
69. Öztürk, H., Özgür, A. & Ozkirimli, E. Deepdta: deep drug–target binding affinity prediction. *Bioinformatics* **34**, i821–i829 (2018).
70. Karimi, M., Wu, D., Wang, Z. & Shen, Y. Deepaffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. *Bioinformatics* **35**, 3329–3338 (2019).

71. Shin, B., Park, S., Kang, K. & Ho, J. C. Self-attention based molecule representation for predicting drug-target interaction. In *Machine Learning for Healthcare Conference*, 230–248 (PMLR, 2019).
72. Gaspar, H. A. *et al.* Proteochemometric models using multiple sequence alignments and a subword segmented masked language model. *ChemRxiv preprint: 14604720.v1* (2021).
73. Wen, M. *et al.* Deep-learning-based drug–target interaction prediction. *J. proteome research* **16**, 1401–1409 (2017).
74. Cheng, Z., Zhao, Q., Li, Y. & Wang, J. Iifdti: predicting drug–target interactions through interactive and independent features based on attention mechanism. *Bioinformatics* (2022).
75. Wallach, I., Dzamba, M. & Heifets, A. Atomnet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. *arXiv preprint arXiv:1510.02855* (2015).
76. Zheng, L., Fan, J. & Mu, Y. Onionnet: a multiple-layer intermolecular-contact-based convolutional neural network for protein–ligand binding affinity prediction. *ACS omega* **4**, 15956–15965 (2019).
77. Lim, J. *et al.* Predicting drug–target interaction using a novel graph neural network with 3d structure-embedded graph representation. *J. chemical information modeling* **59**, 3981–3988 (2019).
78. Cho, H., Lee, E. K. & Choi, I. S. Layer-wise relevance propagation of interactionnet explains protein–ligand interactions at the atom level. *Sci. reports* **10**, 1–11 (2020).
79. Stärk, H., Ganea, O., Pattanaik, L., Barzilay, R. & Jaakkola, T. Equibind: Geometric deep learning for drug binding structure prediction. In *International Conference on Machine Learning*, 20503–20521 (PMLR, 2022).
80. Zhang, Y., Cai, H., Shi, C., Zhong, B. & Tang, J. E3bind: An end-to-end equivariant network for protein-ligand docking. *arXiv preprint arXiv:2210.06069* (2022).
81. Corso, G., Stärk, H., Jing, B., Barzilay, R. & Jaakkola, T. Diffdock: Diffusion steps, twists, and turns for molecular docking. *arXiv preprint arXiv:2210.01776* (2022).
82. Tsubaki, M., Tomii, K. & Sese, J. Compound–protein interaction prediction with end-to-end learning of neural networks for graphs and sequences. *Bioinformatics* **35**, 309–318 (2019).
83. Gligorijević, V. *et al.* Structure-based protein function prediction using graph convolutional networks. *Nat. communications* **12**, 1–14 (2021).
84. Lee, I. & Nam, H. Sequence-based prediction of protein binding regions and drug–target interactions. *J. cheminformatics* **14**, 1–15 (2022).
85. Jiang, M., Li, Z., Bian, Y. & Wei, Z. A novel protein descriptor for the prediction of drug binding sites. *BMC bioinformatics* **20**, 1–13 (2019).
86. Stepniewska-Dziubinska, M. M., Zielenkiewicz, P. & Siedlecki, P. Improving detection of protein-ligand binding sites with 3d segmentation. *Sci. reports* **10**, 1–9 (2020).
87. Kandel, J., Tayara, H. & Chong, K. T. PURESNet: prediction of protein-ligand binding sites using deep residual neural network. *J. cheminformatics* **13**, 1–14 (2021).
88. Tubiana, J., Schneidman-Duhovny, D. & Wolfson, H. J. Scannet: An interpretable geometric deep learning model for structure-based protein binding site prediction. *Nat. Methods* 1–10 (2022).
89. Gainza, P. *et al.* Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning. *Nat. Methods* **17**, 184–192 (2020).
90. Sverrisson, F., Feydy, J., Correia, B. E. & Bronstein, M. M. Fast end-to-end learning on protein surfaces. In *Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition*, 15272–15281 (2021).
91. Mylonas, S. K., Axenopoulos, A. & Daras, P. Deepsurf: a surface-based deep learning approach for the prediction of ligand binding sites on proteins. *Bioinformatics* **37**, 1681–1690 (2021).

92. Grechishnikova, D. Transformer neural network for protein-specific de novo drug generation as a machine translation problem. *Sci. reports* **11**, 1–13 (2021).
93. Uludođan, G., Ozkirimli, E., Ulgen, K. O., Karalı, N. & Özgür, A. Exploiting pretrained biochemical language models for targeted drug design. *Bioinformatics* **38**, ii155–ii161 (2022).
94. Skalic, M., Varela-Rial, A., Jiménez, J., Martínez-Rosell, G. & De Fabritiis, G. Ligvoxel: inpainting binding pockets using 3d-convolutional neural networks. *Bioinformatics* **35**, 243–250 (2019).
95. Ragoza, M., Masuda, T. & Koes, D. R. Generating 3d molecules conditional on receptor binding sites with deep generative models. *Chem. science* **13**, 2701–2713 (2022).
96. Li, Y., Pei, J. & Lai, L. Structure-based de novo drug design using 3d deep generative models. *Chem. science* **12**, 13664–13675 (2021).
97. McNaughton, A. D., Bontha, M. S., Knutson, C. R., Pope, J. A. & Kumar, N. De novo design of protein target specific scaffold-based inhibitors via reinforcement learning. *arXiv preprint arXiv:2205.10473* (2022).
98. Chan, L., Kumar, R., Verdonk, M. & Poelking, C. 3d pride without 2d prejudice: Bias-controlled multi-level generative models for structure-based ligand design. *arXiv preprint arXiv:2204.10663* (2022).
99. Skalic, M., Sabbadin, D., Sattarov, B., Sciabola, S. & De Fabritiis, G. From target to drug: generative modeling for the multimodal structure-based ligand design. *Mol. pharmaceutics* **16**, 4282–4291 (2019).
100. Zhu, H., Zhou, R., Tang, J. & Li, M. Pgm: A pharmacophore-guided deep learning approach for bioactive molecular generation. *arXiv preprint arXiv:2207.00821* (2022).
101. Krishnan, S. R. *et al.* De novo structure-based drug design using deep learning. *J. Chem. Inf. Model.* **62**, 5100–5109 (2021).
102. Zhang, J. & Chen, H. De novo molecule design using molecular generative models constrained by ligand–protein interactions. *J. Chem. Inf. Model.* (2022).
103. Schneuing, A. *et al.* Structure-based drug design with equivariant diffusion models. *arXiv preprint arXiv:2210.13695* (2022).
104. Igashov, I. *et al.* Equivariant 3d-conditional diffusion models for molecular linker design. *arXiv preprint arXiv:2210.05274* (2022).
105. Bagherian, M. *et al.* Machine learning approaches and databases for prediction of drug–target interaction: a survey paper. *Briefings Bioinforma.* **22**, 247–269, DOI: 10.1093/bib/bbz157 (2020). <https://academic.oup.com/bib/article-pdf/22/1/247/35935006/bbz157.pdf>.
106. Abbasi, K. *et al.* Deepcda: deep cross-domain compound–protein affinity prediction through lstm and convolutional neural networks. *Bioinformatics* **36**, 4633–4642 (2020).
107. Zhao, Q. *et al.* Attentiondta: drug-target binding affinity prediction by sequence-based deep learning with attention mechanism. *IEEE/ACM Transactions on Comput. Biol. Bioinforma.* (2022).
108. Monteiro, N. R., Oliveira, J. L. & Arrais, J. P. Dtitr: End-to-end drug–target binding affinity prediction with transformers. *Comput. Biol. Medicine* **147**, 105772 (2022).
109. Öztürk, H., Ozkirimli, E. & Özgür, A. Widedta: prediction of drug-target binding affinity. *arXiv preprint arXiv:1902.04166* (2019).
110. Özçelik, R., Öztürk, H., Özgür, A. & Ozkirimli, E. Chemboost: A chemical language based approach for protein–ligand binding affinity prediction. *Mol. Informatics* **40**, 2000212 (2021).
111. Feng, Q., Dueva, E., Cherkasov, A. & Ester, M. Padme: A deep learning-based framework for drug-target interaction prediction. *arXiv preprint arXiv:1807.09741* (2018).
112. O’Boyle, N. & Dalke, A. Deepsmiles: an adaptation of smiles for use in machine-learning of chemical structures. *ChemRxiv preprint: 7097960.v1* (2018).

113. Lee, I., Keum, J. & Nam, H. Deepconv-dti: Prediction of drug-target interactions via deep learning with convolution on protein sequences. *PLoS computational biology* **15**, e1007129 (2019).
114. Nguyen, T. *et al.* Graphdta: Predicting drug–target binding affinity with graph neural networks. *Bioinformatics* **37**, 1140–1147 (2021).
115. Wang, J. & Dokholyan, N. V. Yuel: Improving the generalizability of structure-free compound–protein interaction prediction. *J. Chem. Inf. Model.* **62**, 463–471 (2022).
116. Jiménez, J., Skalic, M., Martínez-Rosell, G. & De Fabritiis, G. K deep: protein–ligand absolute binding affinity prediction via 3d-convolutional neural networks. *J. chemical information modeling* **58**, 287–296 (2018).
117. Hassan-Harrirou, H., Zhang, C. & Lemmin, T. Rosenet: improving binding affinity prediction by leveraging molecular mechanics energies with an ensemble of 3d convolutional neural networks. *J. chemical information modeling* **60**, 2791–2802 (2020).
118. Jiménez-Luna, J. *et al.* Deltadelta neural networks for lead optimization of small molecule potency. *Chem. science* **10**, 10911–10918 (2019).
119. McNutt, A. T. & Koes, D. R. Improving $\delta\delta g$ predictions with a multitask convolutional siamese network. *J. Chem. Inf. Model.* **62**, 1819–1829 (2022).
120. Torng, W. & Altman, R. B. Graph convolutional neural networks for predicting drug-target interactions. *J. chemical information modeling* **59**, 4131–4149 (2019).
121. Liu, Q. *et al.* Octsurf: Efficient hierarchical voxel-based molecular surface representation for protein-ligand affinity prediction. *J. Mol. Graph. Model.* **105**, 107865 (2021).
122. Somnath, V. R., Bunne, C. & Krause, A. Multi-scale representation learning on proteins. *Adv. Neural Inf. Process. Syst.* **34**, 25244–25255 (2021).
123. Qiao, Z., Nie, W., Vahdat, A., Miller III, T. F. & Anandkumar, A. Dynamic-backbone protein-ligand structure prediction with multiscale generative diffusion models. *arXiv preprint arXiv:2209.15171* (2022).
124. Pereira, J. C., Caffarena, E. R. & Dos Santos, C. N. Boosting docking-based virtual screening with deep learning. *J. chemical information modeling* **56**, 2495–2506 (2016).
125. Gentile, F. *et al.* Deep docking: a deep learning platform for augmentation of structure based drug discovery. *ACS central science* **6**, 939–949 (2020).
126. Wang, X., Terashi, G., Christoffer, C. W., Zhu, M. & Kihara, D. Protein docking model evaluation by 3d deep convolutional neural networks. *Bioinformatics* **36**, 2113–2118 (2020).
127. McNutt, A. T. *et al.* Gnina 1.0: molecular docking with deep learning. *J. cheminformatics* **13**, 1–20 (2021).
128. Zhang, H., Liao, L., Saravanan, K. M., Yin, P. & Wei, Y. Deepbindrg: a deep learning based method for estimating effective protein–ligand affinity. *PeerJ* **7**, e7362 (2019).
129. Morrone, J. A., Weber, J. K., Huynh, T., Luo, H. & Cornell, W. D. Combining docking pose rank and structure with deep learning improves protein–ligand binding mode prediction over a baseline docking approach. *J. chemical information modeling* **60**, 4170–4179 (2020).
130. Méndez-Lucio, O., Ahmad, M., del Rio-Chanona, E. A. & Wegner, J. K. A geometric deep learning approach to predict binding conformations of bioactive molecules. *Nat. Mach. Intell.* **3**, 1033–1039 (2021).
131. Stafford, K. A., Anderson, B. M., Sorenson, J. & van den Bedem, H. Atomnet poseranker: Enriching ligand pose quality for dynamic proteins in virtual high-throughput screens. *J. chemical information modeling* **62**, 1178–1189 (2022).
132. Masters, M., Mahmoud, A. H., Wei, Y. & Lill, M. A. Deep learning model for flexible and efficient protein-ligand docking. In *ICLR2022 Machine Learning for Drug Discovery* (2022).
133. Volkov, M. *et al.* On the frustration to predict binding affinities from protein–ligand structures with deep neural networks. *J. Medicinal Chem.* (2022).

134. Peng, K., Obradovic, Z. & Vucetic, S. Exploring bias in the protein data bank using contrast classifiers. In *Biocomputing 2004*, 435–446 (World Scientific, 2003).
135. Chaput, L., Martinez-Sanz, J., Saettel, N. & Mouawad, L. Benchmark of four popular virtual screening programs: construction of the active/decoy dataset remains a major determinant of measured performance. *J. cheminformatics* **8**, 1–17 (2016).
136. Chen, L. *et al.* Hidden bias in the dud-e dataset leads to misleading performance of deep learning in structure-based virtual screening. *PloS one* **14**, e0220113 (2019).
137. Tran-Nguyen, V.-K., Jacquemard, C. & Rognan, D. Lit-pcba: An unbiased data set for machine learning and virtual screening. *J. chemical information modeling* **60**, 4263–4273 (2020).
138. Özçelik, R. *et al.* Debiaseddta: Improving the generalizability of drug-target affinity prediction models. *arXiv preprint arXiv:2107.05556* (2022).
139. Zhu, H., Yang, J. & Huang, N. Assessment of the generalization abilities of machine-learning scoring functions for structure-based virtual screening. *J. Chem. Inf. Model.* DOI: 10.1021/acs.jcim.2c01149 (2022). PMID: 36268980, <https://doi.org/10.1021/acs.jcim.2c01149>.
140. Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A.-C. & Villoutreix, B. O. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. *Drug discovery today* **15**, 656–667 (2010).
141. Zhao, J., Cao, Y. & Zhang, L. Exploring the computational methods for protein-ligand binding site prediction. *Comput. Struct. Biotechnol. J.* **18**, 417–426 (2020).
142. Laskowski, R. A. Surfnet: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. *J. molecular graphics* **13**, 323–330 (1995).
143. Brady, G. P. & Stouten, P. F. Fast prediction and visualization of protein binding pockets with pass. *J. computer-aided molecular design* **14**, 383–401 (2000).
144. Capra, J. A., Laskowski, R. A., Thornton, J. M., Singh, M. & Funkhouser, T. A. Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3d structure. *PLoS computational biology* **5**, e1000585 (2009).
145. Weisel, M., Proschak, E. & Schneider, G. Pocketpicker: analysis of ligand binding-sites with shape descriptors. *Chem. Cent. J.* **1**, 1–17 (2007).
146. Cui, Y., Dong, Q., Hong, D. & Wang, X. Predicting protein-ligand binding residues with deep convolutional neural networks. *BMC bioinformatics* **20**, 1–12 (2019).
147. Khan, S. H., Tayara, H. & Chong, K. T. Prob-site: Protein binding site prediction using local features. *Cells* **11**, 2117 (2022).
148. Kozlovskii, I. & Popov, P. Spatiotemporal identification of druggable binding sites using deep learning. *Commun. biology* **3**, 1–12 (2020).
149. Kozlovskii, I. & Popov, P. Protein–peptide binding site detection using 3d convolutional neural networks. *J. chemical information modeling* **61**, 3814–3823 (2021).
150. Krivák, R. & Hoksza, D. P2rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure. *J. cheminformatics* **10**, 1–12 (2018).
151. Gagliardi, L. *et al.* Shrec 2022: Protein–ligand binding site recognition. *Comput. & Graph.* **107**, 20–31, DOI: <https://doi.org/10.1016/j.cag.2022.07.005> (2022).
152. Ni, D. *et al.* Along the allostery stream: Recent advances in computational methods for allosteric drug discovery. *WIREs Comput. Mol. Sci.* **12**, e1585, DOI: <https://doi.org/10.1002/wcms.1585> (2022). <https://wires.onlinelibrary.wiley.com/doi/pdf/10.1002/wcms.1585>.
153. Schneider, P. & Schneider, G. De novo design at the edge of chaos. *J. Medicinal Chem.* **59**, 4077–4086 (2016).

154. Ertl, P. Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. *J. chemical information computer sciences* **43**, 374–380 (2003).
155. Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. *Nature* **432**, 855–861 (2004).
156. Olivecrona, M., Blaschke, T., Engkvist, O. & Chen, H. Molecular de-novo design through deep reinforcement learning. *J. cheminformatics* **9**, 1–14 (2017).
157. Devi, R. V., Sathya, S. S. & Coumar, M. S. Evolutionary algorithms for de novo drug design—a survey. *Appl. Soft Comput.* **27**, 543–552 (2015).
158. Douguet, D., Thoreau, E. & Grassy, G. A genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm. *J. computer-aided molecular design* **14**, 449–466 (2000).
159. Ferreira, L. G., Dos Santos, R. N., Oliva, G. & Andricopulo, A. D. Molecular docking and structure-based drug design strategies. *Molecules* **20**, 13384–13421 (2015).
160. Li, Y., Vinyals, O., Dyer, C., Pascanu, R. & Battaglia, P. Learning deep generative models of graphs. *arXiv preprint arXiv:1803.03324* (2018).
161. Samanta, B. *et al.* Nevae: A deep generative model for molecular graphs. *J. machine learning research*. 2020 Apr; 21 (114): 1-33 (2020).
162. De Cao, N. & Kipf, T. Molgan: An implicit generative model for small molecular graphs. *arXiv preprint arXiv:1805.11973* (2018).
163. Popova, M., Isayev, O. & Tropsha, A. Deep reinforcement learning for de novo drug design. *Sci. advances* **4**, eaap7885 (2018).
164. Ståhl, N., Falkman, G., Karlsson, A., Mathiason, G. & Bostrom, J. Deep reinforcement learning for multiparameter optimization in de novo drug design. *J. chemical information modeling* **59**, 3166–3176 (2019).
165. Gupta, A. *et al.* Generative recurrent networks for de novo drug design. *Mol. informatics* **37**, 1700111 (2018).
166. Moret, M., Friedrich, L., Grisoni, F., Merk, D. & Schneider, G. Generative molecular design in low data regimes. *Nat. Mach. Intell.* **2**, 171–180 (2020).
167. Filipavicius, M., Manica, M., Cadow, J. & Martinez, M. R. Pre-training protein language models with label-agnostic binding pairs enhances performance in downstream tasks. *arXiv preprint arXiv:2012.03084* (2020).
168. Chithrananda, S., Grand, G. & Ramsundar, B. Chemberta: large-scale self-supervised pretraining for molecular property prediction. *arXiv preprint arXiv:2010.09885* (2020).
169. Powers, A., Yu, H., Suriana, P. & Dror, R. Fragment-based ligand generation guided by geometric deep learning on protein-ligand structure. *bioRxiv* (2022).
170. Flam-Shepherd, D., Zhu, K. & Aspuru-Guzik, A. Language models can learn complex molecular distributions. *Nat. Commun.* **13**, 1–10 (2022).
171. Goodfellow, I. *et al.* Generative adversarial nets. *Adv. neural information processing systems* **27** (2014).
172. Grisoni, F. *et al.* Combining generative artificial intelligence and on-chip synthesis for de novo drug design. *Sci. Adv.* **7**, eabg3338 (2021).
173. Moret, M., Helmstädter, M., Grisoni, F., Schneider, G. & Merk, D. Beam search for automated design and scoring of novel ror ligands with machine intelligence. *Angewandte Chemie Int. Ed.* **60**, 19477–19482 (2021).
174. Schmidhuber, J., Hochreiter, S. *et al.* Long short-term memory. *Neural Comput.* **9**, 1735–1780 (1997).
175. Hatzakis, N. S. Single molecule insights on conformational selection and induced fit mechanism. *Biophys. chemistry* **186**, 46–54 (2014).

176. Bronstein, M. M., Bruna, J., LeCun, Y., Szlam, A. & Vandergheynst, P. Geometric deep learning: going beyond euclidean data. *IEEE Signal Process. Mag.* **34**, 18–42 (2017).
177. Zhang, S., Liu, Y. & Xie, L. Efficient and accurate physics-aware multiplex graph neural networks for 3d small molecules and macromolecule complexes. *arXiv preprint arXiv:2206.02789* (2022).
178. Gainza, P. *et al.* De novo design of site-specific protein interactions with learned surface fingerprints. *bioRxiv* (2022).
179. Sohl-Dickstein, J., Weiss, E., Maheswaranathan, N. & Ganguli, S. Deep unsupervised learning using nonequilibrium thermodynamics. In *International Conference on Machine Learning*, 2256–2265 (PMLR, 2015).
180. Hoogeboom, E., Satorras, V. G., Vignac, C. & Welling, M. Equivariant diffusion for molecule generation in 3d. In *International Conference on Machine Learning*, 8867–8887 (PMLR, 2022).
181. Davis, A. M., Teague, S. J. & Kleywegt, G. J. Application and limitations of x-ray crystallographic data in structure-based ligand and drug design. *Angewandte Chemie Int. Ed.* **42**, 2718–2736 (2003).
182. Shah, H., Tamuly, K., Raghunathan, A., Jain, P. & Netrapalli, P. The pitfalls of simplicity bias in neural networks. *Adv. Neural Inf. Process. Syst.* **33**, 9573–9585 (2020).
183. Sieg, J., Flachsenberg, F. & Rarey, M. In need of bias control: evaluating chemical data for machine learning in structure-based virtual screening. *J. chemical information modeling* **59**, 947–961 (2019).
184. Boyles, F., Deane, C. M. & Morris, G. M. Learning from the ligand: using ligand-based features to improve binding affinity prediction. *Bioinformatics* **36**, 758–764 (2020).
185. Wallach, I. & Heifets, A. Most ligand-based classification benchmarks reward memorization rather than generalization. *J. chemical information modeling* **58**, 916–932 (2018).
186. Gonczarek, A. *et al.* Interaction prediction in structure-based virtual screening using deep learning. *Comput. biology medicine* **100**, 253–258 (2018).
187. Scantlebury, J., Brown, N., Von Delft, F. & Deane, C. M. Data set augmentation allows deep learning-based virtual screening to better generalize to unseen target classes and highlight important binding interactions. *J. chemical information modeling* **60**, 3722–3730 (2020).
188. Sundar, V. & Colwell, L. The effect of debiasing protein–ligand binding data on generalization. *J. Chem. Inf. Model.* **60**, 56–62 (2019).
189. Goebel, R. *et al.* Explainable ai: The new 42? In Holzinger, A., Kieseberg, P., Tjoa, A. M. & Weippl, E. (eds.) *Machine Learning and Knowledge Extraction*, 295–303 (Springer International Publishing, Cham, 2018).
190. Jiménez-Luna, J., Grisoni, F. & Schneider, G. Drug discovery with explainable artificial intelligence. *Nat. Mach. Intell.* **2**, 573–584 (2020).